US Pharma MarketingThe fundraise is the firm’s largest to date, providing a lift for a European biotech industry that’s fallen further behind its counterparts in the U.S. and China.
Forbion, a prominent biotech investor, raises $2.6B for a pair of venture funds
The fundraise is the firm’s largest to date, providing a lift for a European biotech industry that’s fallen further behind its counterparts in the U.S. and China.
Source: BioPharma Dive